Jrg B. Schulz

List of Publications by Citations

384 papers	28,154 citations	85 h-index	157 g-index
416 ext. papers	31,058 ext. citations	6.3 avg, IF	6.67 L-index

#	Paper	IF	Citations
384	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology*, **2005**, 65, 1863-72	6.5	3921
383	Glutathione, oxidative stress and neurodegeneration. *FEBS Journal*, **2000**, 267, 4904-11		886
382	Modelling neural correlates of working memory: a coordinate-based meta-analysis. *NeuroImage*, **2012**, 60, 830-46	7.9	581
381	Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. *Stroke*, **2003**, 34, 813-9	6.7	491
380	Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **1993**, 61, 2322-5	6	473
379	Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. *Human Molecular Genetics*, **2005**, 14, 2099-111	5.6	446
378	Repetitive bilateral arm training and motor cortex activation in chronic stroke: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1853-61	27.4	411
377	Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. *Nature Genetics*, **2004**, 36, 225-7	36.3	385
376	Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. *EMBO Journal*, **2009**, 28, 3256-68	13	348
375	Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. *Journal of Neurochemistry*, **1995**, 64, 936-9	6	332
374	Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. *Molecular and Cellular Biology*, **2004**, 24, 9848-62	4.8	327
373	Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. *Journal of Neuroscience*, **1996**, 16, 4696-706	6.6	317
372	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. *Annals of Neurology*, **2002**, 52, 346-50	9.4	304
371	Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. *Journal of Neurochemistry*, **2004**, 88, 494-501	6	299
370	Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. *Cell and Tissue Research*, **2004**, 318, 149-61	4.2	296
369	Caspases as treatment targets in stroke and neurodegenerative diseases. *Annals of Neurology*, **1999**, 45, 421-9	9.4	288
368	Transgenic rat model of Huntington's disease. *Human Molecular Genetics*, **2003**, 12, 617-24	5.6	286

367	Involvement of free radicals in excitotoxicity in vivo. *Journal of Neurochemistry*, **1995**, 64, 2239-47	6	265
366	Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. *Journal of Neurochemistry*, **2000**, 74, 2213-6	6	262
365	Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 7606-11	11.5	261
364	Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. *Journal of Neuroscience*, **2002**, 22, 6401-7	6.6	252
363	Update on the pathogenesis of Parkinson's disease. *Journal of Neurology*, **2008**, 255 Suppl 5, 3-7	5.5	232
362	Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. *Annals of Neurology*, **1999**, 45, 65-74	9.4	232
361	Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. *Science*, **2008**, 320, 520-3	33.3	225
360	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. *Molecular Cancer*, **2011**, 10, 128	42.1	223
359	Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. *Annals of Neurology*, **1997**, 42, 326-34	9.4	221
358	Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. *Journal of Clinical Investigation*, **2004**, 114, 1741-51	15.9	206
357	Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 10433-8	11.5	198
356	Current and experimental treatments of Parkinson disease: A guide for neuroscientists. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 325-337	6	196
355	Diagnosis and treatment of Friedreich ataxia: a European perspective. *Nature Reviews Neurology*, **2009**, 5, 222-34	15	192
354	Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. *EMBO Journal*, **2010**, 29, 209-21	13	185
353	Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. *Journal of Neuroscience*, **2000**, 20, 9126-34	6.6	184
352	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. *Journal of Neuroscience*, **1998**, 18, 8145-52	6.6	181
351	Deep brain stimulation. *Cell and Tissue Research*, **2004**, 318, 275-88	4.2	180
350	Neuroprotection by the inhibition of apoptosis. *Brain Pathology*, **2000**, 10, 283-92	6	174

349	Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. *Annals of Neurology*, **1994**, 36, 882-8	9.4	172
348	Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8161-6	11.5	170
347	Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. *Brain Research*, **1997**, 753, 157-62	3.7	164
346	Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. *Journal of Neurochemistry*, **1998**, 71, 88-94	6	161
345	Patterns of age-related shrinkage in cerebellum and brainstem observed in vivo using three-dimensional MRI volumetry. *Cerebral Cortex*, **1999**, 9, 712-21	5.1	159
344	Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. *Brain Research*, **1999**, 826, 53-62	3.7	154
343	Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. *Journal of Neurology, Neurosurgery and Psychiatry*, **1994**, 57, 1047-56	5.5	152
342	The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. *Neurology*, **2011**, 77, 1035-41	6.5	150
341	TDP-43-mediated neuron loss in vivo requires RNA-binding activity. *PLoS ONE*, **2010**, 5, e12247	3.7	149
340	PML in a patient treated with fumaric acid. *New England Journal of Medicine*, **2013**, 368, 1657-8	59.2	148
339	The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. *Journal of Neurochemistry*, **2006**, 97, 373-84	6	146
338	Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. *Journal of Neuroscience*, **2008**, 28, 2471-84	6.6	144
337	The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. *Journal of Neurochemistry*, **2001**, 76, 627-36	6	142
336	Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. *Brain*, **1998**, 121 (Pt 9), 1687-93	11.2	142
335	Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. *Lancet Neurology, The*, **2015**, 14, 1101-8	24.1	139
334	The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. *Molecular and Cellular Biochemistry*, **1997**, 174, 193-197	4.2	139
333	Short and long-term motor skill learning in an accelerated rotarod training paradigm. *Neurobiology of Learning and Memory*, **2004**, 81, 211-6	3.1	139
332	Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. *NeuroReport*, **1996**, 7, 921-3	1.7	139

331	Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. *Neuroscience*, **1996**, 71, 1043-8	3.9	138
330	Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. *Journal of Cell Biology*, **2002**, 157, 327-36	7.3	136
329	Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. *Molecular and Cellular Neurosciences*, **2001**, 17, 78-96	4.8	136
328	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. *NeuroImage*, **2004**, 21, 714-24	7.9	135
327	Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. *NeuroImage*, **2010**, 49, 158-68	7.9	133
326	Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. *Journal of Biological Chemistry*, **2008**, 283, 12681-5	5.4	123
325	Systematic review of early recurrent stenosis after carotid angioplasty and stenting. *Stroke*, **2005**, 36, 367-73	6.7	123
324	Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. *Neurochemistry International*, **1996**, 29, 167-71	4.4	123
323	Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. *Journal of Neuroscience Research*, **2002**, 69, 318-26	4.4	121
322	Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. *Lancet Neurology, The*, **2013**, 12, 650-8	24.1	120
321	Drosophila melanogaster as a model organism for Alzheimer's disease. *Molecular Neurodegeneration*, **2013**, 8, 35	19	120
320	Lesion location alters brain activation in chronically impaired stroke survivors. *NeuroImage*, **2004**, 21, 924-35	7.9	118
319	Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. *Journal of Neurochemistry*, **2001**, 77, 1181-4	6	118
318	Motor skill learning depends on protein synthesis in motor cortex after training. *Journal of Neuroscience*, **2004**, 24, 6515-20	6.6	116
317	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. *Lancet Neurology, The*, **2015**, 14, 174-82	24.1	113
316	Responsiveness of different rating instruments in spinocerebellar ataxia patients. *Neurology*, **2010**, 74, 678-84	6.5	112
315	Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. *Human Molecular Genetics*, **2003**, 12, 1223-31	5.6	110
314	The mitochondrial chaperone protein TRAP1 mitigates ⊟Synuclein toxicity. *PLoS Genetics*, **2012**, 8, e1002488	6	105

313	Comparison of three clinical rating scales in Friedreich ataxia (FRDA). *Movement Disorders*, **2009**, 24, 1779-84	7	104
312	Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). *Human Mutation*, **2004**, 24, 321-9	4.7	104
311	Adenovirus-mediated gene transfer of inhibitors of apoptosis protein delays apoptosis in cerebellar granule neurons. *Journal of Neurochemistry*, **1999**, 72, 292-301	6	99
310	Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. *Toxicology Letters*, **2003**, 139, 135-51	4.4	97
309	The Montreal Cognitive Assessment (MoCA) - a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. *PLoS ONE*, **2014**, 9, e106700	3.7	96
308	Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. *Journal of Neurochemistry*, **2006**, 97, 675-86	6	96
307	Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. *Brain*, **2013**, 136, 905-17	11.2	92
306	NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. *Brain Research*, **1996**, 713, 178-85	3.7	92
305	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. *Cell Death and Differentiation*, **1998**, 5, 847-57	12.7	89
304	Relation between regional functional MRI activation and vascular reactivity to carbon dioxide during normal aging. *Journal of Cerebral Blood Flow and Metabolism*, **2003**, 23, 565-73	7.3	88
303	Malonate produces striatal lesions by indirect NMDA receptor activation. *Brain Research*, **1994**, 647, 161-67	3.7	87
302	Role of nitric oxide in neurodegenerative diseases. *Current Opinion in Neurology*, **1995**, 8, 480-6	7.1	86
301	The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. *Circulation*, **2012**, 125, 1626-34	16.7	85
300	Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. *Journal of Neurochemistry*, **2001**, 77, 263-73	6	85
299	Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. *Journal of Neurochemistry*, **1997**, 69, 2075-86	6	83
298	Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. *Experimental Neurology*, **1995**, 132, 279-83	5.7	83
297	Exogenous administration of gangliosides displaces GPI-anchored proteins from lipid microdomains in living cells. *Molecular Biology of the Cell*, **1999**, 10, 3187-96	3.5	82
296	Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. *Journal of Cerebral Blood Flow and Metabolism*, **1995**, 15, 619-23	7.3	81

295	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. *Lancet Neurology, The*, **2016**, 15, 1346-1354	24.1	78
294	Feasibility of prehospital teleconsultation in acute stroke--a pilot study in clinical routine. *PLoS ONE*, **2012**, 7, e36796	3.7	76
293	Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. *Journal of Cerebral Blood Flow and Metabolism*, **1996**, 16, 450-61	7.3	76
292	TRAP1 rescues PINK1 loss-of-function phenotypes. *Human Molecular Genetics*, **2013**, 22, 2829-41	5.6	74
291	Co-enzyme Q10 and idebenone use in Friedreich's ataxia. *Journal of Neurochemistry*, **2013**, 126 Suppl 1, 125-41	6	74
290	Neuronal pathology in Parkinson's disease. *Cell and Tissue Research*, **2004**, 318, 135-47	4.2	73
289	Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. *Molecular and Cellular Neurosciences*, **2001**, 17, 717-31	4.8	73
288	Differentiated parietal connectivity of frontal regions for "what" and "where" memory. *Brain Structure and Function*, **2013**, 218, 1551-67	4	72
287	Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. *Molecular Therapy*, **2012**, 20, 534-43	11.7	72
286	Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. *Dementia and Geriatric Cognitive Disorders*, **2012**, 33, 379-84	2.6	72
285	A new semiautomated, three-dimensional technique allowing precise quantification of total and regional cerebellar volume using MRI. *Magnetic Resonance in Medicine*, **1998**, 40, 143-51	4.4	71
284	Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. *International Journal of Biological Sciences*, **2007**, 3, 242-50	11.2	70
283	Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death. *Radiology*, **2006**, 240, 145-51	20.5	69
282	Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. *Journal of Neurochemistry*, **2008**, 105, 853-64	6	67
281	Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. *Stroke*, **2005**, 36, 787-91	6.7	67
280	Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. *Journal of Neurochemistry*, **1996**, 67, 430-3	6	67
279	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. *Neurobiology of Disease*, **2006**, 23, 573-7	7.5	66
278	Comparison of angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients. *Journal of Vascular Surgery*, **2004**, 40, 945-51	3.5	66

277	Mitochondrial dysfunction in movement disorders. *Current Opinion in Neurology*, **1994**, 7, 333-9	7.1	66
276	Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. *Cerebellum*, **2012**, 11, 155-66	4.3	65
275	Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. *Neuroscience Letters*, **1999**, 264, 1-4	3.3	63
274	Characterization of motor skill and instrumental learning time scales in a skilled reaching task in rat. *Behavioural Brain Research*, **2004**, 155, 249-56	3.4	62
273	Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. *Annals of Neurology*, **2001**, 50, 827-8	9.4	62
272	Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from the German mitoNET registry. *Journal of Neurology*, **2016**, 263, 961-972	5.5	61
271	Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. *Journal of Neurology*, **2013**, 260, 3093-108	5.5	61
270	Drosophila as a screening tool to study human neurodegenerative diseases. *Journal of Neurochemistry*, **2013**, 127, 453-60	6	61
269	Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. *Journal of Neurochemistry*, **2002**, 82, 458-67	6	60
268	Altered resting-state connectivity in Huntington's disease. *Human Brain Mapping*, **2014**, 35, 2582-93	5.9	59
267	Investigating function and connectivity of morphometric findings--exemplified on cerebellar atrophy in spinocerebellar ataxia 17 (SCA17). *NeuroImage*, **2012**, 62, 1354-66	7.9	59
266	Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. *Neurology*, **2006**, 66, 949-50	6.5	59
265	Parkinson's disease: one biochemical pathway to fit all genes?. *Trends in Molecular Medicine*, **2002**, 8, 236-40	11.5	59
264	Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. *Journal of Neurochemistry*, **2008**, 106, 529-40	6	57
263	High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. *Human Molecular Genetics*, **1999**, 8, 1169-76	5.6	57
262	Consensus clinical management guidelines for Friedreich ataxia. *Orphanet Journal of Rare Diseases*, **2014**, 9, 184	4.2	56
261	Depression comorbidity in spinocerebellar ataxia. *Movement Disorders*, **2011**, 26, 870-6	7	56
260	Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis. *Neurobiology of Disease*, **2002**, 11, 123-33	7.5	56

259	Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1099-105	5.5	56
258	The cancer stem cell subtype determines immune infiltration of glioblastoma. *Stem Cells and Development*, **2012**, 21, 2753-61	4.4	55
257	Long-term EMG recordings differentiate between parkinsonian and essential tremor. *Journal of Neurology*, **2008**, 255, 103-11	5.5	55
256	Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. *Journal of Cerebral Blood Flow and Metabolism*, **1995**, 15, 948-52	7.3	55
255	Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. *Brain Structure and Function*, **2012**, 217, 115-25	4	53
254	Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) - A systematic review on potential biomarkers for neurodegeneration. *Sleep Medicine Reviews*, **2017**, 34, 23-33	10.2	52
253	Clinical experience with high-dose idebenone in Friedreich ataxia. *Journal of Neurology*, **2009**, 256 Suppl 1, 42-5	5.5	52
252	Self-rated health status in spinocerebellar ataxia--results from a European multicenter study. *Movement Disorders*, **2010**, 25, 587-95	7	52
251	Magnetic resonance imaging in spinocerebellar ataxias. *Cerebellum*, **2008**, 7, 204-14	4.3	52
250	Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. *Journal of Neurochemistry*, **1999**, 73, 1329-32	6	52
249	Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. *Orphanet Journal of Rare Diseases*, **2017**, 12, 86	4.2	51
248	Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis. *Neurodegenerative Diseases*, **2013**, 12, 23-35	2.3	51
247	Cortical stimulation mapping using epidurally implanted thin-film microelectrode arrays. *Journal of Neuroscience Methods*, **2007**, 161, 118-25	3	51
246	Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model. *European Journal of Neuroscience*, **2006**, 24, 2275-82	3.5	51
245	Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. *Journal of Neurochemistry*, **2004**, 91, 1067-74	6	51
244	COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. *Annals of Neurology*, **2021**, 90, 627-639	9.4	51
243	Increased brain tissue sodium concentration in Huntington's Disease - a sodium imaging study at 4 T. *NeuroImage*, **2012**, 63, 517-24	7.9	50
242	Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. *Cell Death and Differentiation*, **1998**, 5, 894-900	12.7	50

241	RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20049-54	11.5	49
240	MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). *Experimental Cell Research*, **1999**, 250, 75-85	4.2	49
239	Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. *Human Molecular Genetics*, **2015**, 24, 3623-37	5.6	48
238	UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. *Journal of Biological Chemistry*, **2014**, 289, 19164-79	5.4	48
237	Frequent genes in rare diseases: panel-based next generation sequencing to disclose causal mutations in hereditary neuropathies. *Journal of Neurochemistry*, **2017**, 143, 507-522	6	48
236	Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. *Neurobiology of Aging*, **2012**, 33, 2478-90	5.6	48
235	FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. *Journal of Neuroscience*, **2005**, 25, 6765-74	6.6	47
234	Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. *Lancet Neurology, The*, **2018**, 17, 327-334	24.1	46
233	Visualization and quantification of disease progression in multiple system atrophy. *Movement Disorders*, **2006**, 21, 1674-81	7	46
232	Rab7 induces clearance of □synuclein aggregates. *Journal of Neurochemistry*, **2016**, 138, 758-74	6	46
231	Intracellular acidification by inhibition of the Na+/H+-exchanger leads to caspase-independent death of cerebellar granule neurons resembling paraptosis. *Cell Death and Differentiation*, **2004**, 11, 760-70	12.7	45
230	Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. *Journal of Neurochemistry*, **2013**, 126 Suppl 1, 118-24	6	44
229	Targeted ablation of oligodendrocytes triggers axonal damage. *PLoS ONE*, **2011**, 6, e22735	3.7	44
228	Lactate as a diagnostic marker in transient loss of consciousness. *Seizure: the Journal of the British Epilepsy Association*, **2016**, 40, 71-5	3.2	43
227	Clinical predictors of individual cognitive fluctuations in patients undergoing hemodialysis. *American Journal of Kidney Diseases*, **2014**, 64, 434-42	7.4	43
226	Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model. *Cell Death and Disease*, **2016**, 7, e2359	9.8	43
225	Blood-based neurochemical diagnosis of vascular dementia: a pilot study. *Journal of Neurochemistry* , **2007**, 103, 467-74	6	41
224	The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. *FASEB Journal*, **2007**, 21, 1759-67	0.9	41

223	MRI-based volumetric differentiation of sporadic cerebellar ataxia. *Brain*, **2004**, 127, 175-81	11.2	41
222	Clinical and magnetic resonance imaging characteristics of sporadic cerebellar ataxia. *Archives of Neurology*, **2005**, 62, 981-5		41
221	Unilateral lesion of the pedunculopontine nucleus induces hyperactivity in the subthalamic nucleus and substantia nigra in the rat. *European Journal of Neuroscience*, **2005**, 22, 2283-94	3.5	41
220	Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. *Brain*, **2013**, 136, 259-68	11.2	40
219	Palmitoylation is a sorting determinant for transport to the myelin membrane. *Journal of Cell Science*, **2005**, 118, 2415-23	5.3	40
218	Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. *Neurochemistry International*, **2000**, 36, 489-97	4.4	40
217	Cognition in Friedreich's ataxia: a behavioral and multimodal imaging study. *Annals of Clinical and Translational Neurology*, **2016**, 3, 572-87	5.3	39
216	Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. *Neuroscience Letters*, **2008**, 440, 68-71	3.3	39
215	Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. *Journal of Neurochemistry*, **2001**, 79, 63-70	6	39
214	Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar neurons. *Neuroscience Letters*, **2000**, 282, 69-72	3.3	38
213	□-antitrypsin mitigates NLRP3-inflammasome activation in amyloid □stimulated murine astrocytes. *Journal of Neuroinflammation*, **2018**, 15, 282	10.1	38
212	Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI studies. *NeuroImage: Clinical*, **2019**, 23, 101933	5.3	36
211	Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia. *Journal of Neuroscience*, **2011**, 31, 225-33	6.6	36
210	Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity?. *Trends in Neurosciences*, **2008**, 31, 478-86	13.3	36
209	Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy?. *European Journal of Neurology*, **2015**, 22, 806-14, e55	6	35
208	Parkinson's disease and dementia: a longitudinal study (DEMPARK). *Neuroepidemiology*, **2011**, 37, 168-76	5.4	35
207	3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. *Journal of Cerebral Blood Flow and Metabolism*, **1994**, 14, 1024-9	7.3	35
206	Consensus paper: radiological biomarkers of cerebellar diseases. *Cerebellum*, **2015**, 14, 175-96	4.3	34

205	Clinical and biometrical 12-month follow-up in patients after reconstruction of the sural nerve biopsy defect by the collagen-based nerve guide Neuromaix. *European Journal of Medical Research*, **2017**, 22, 34	4.8	34
204	Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6-hydroxydopamine rat model. *Journal of Neuroscience Research*, **2008**, 86, 1388-96	4.4	34
203	Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2014**, 37, 95-103	2.6	33
202	Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. *Synapse*, **1997**, 26, 381-91	2.4	33
201	Lewy body dementia and Parkinson's disease with dementia. *Journal of Neurology*, **2008**, 255 Suppl 5, 39-47	5.5	33
200	Mechanisms of neurodegeneration in idiopathic Parkinson's disease. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S306-8	3.6	33
199	Early outcome of carotid angioplasty and stenting versus carotid endarterectomy in a single academic center. *Cerebrovascular Diseases*, **2003**, 15, 84-9	3.2	33
198	Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice. *EMBO Journal*, **2016**, 35, 2008-25	13	33
197	Analysis of drug-related problems in three departments of a German University hospital. *International Journal of Clinical Pharmacy*, **2016**, 38, 119-26	2.3	32
196	Neural correlates of impaired emotion processing in manifest Huntington's disease. *Social Cognitive and Affective Neuroscience*, **2014**, 9, 671-80	4	32
195	Nonataxia symptoms in Friedreich Ataxia: Report from the Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS). *Neurology*, **2018**, 91, e917-e930	6.5	31
194	Case reports of PML in patients treated for psoriasis. *New England Journal of Medicine*, **2013**, 369, 1081	59.2	31
193	Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. *Neurobiology of Disease*, **2015**, 74, 76-88	7.5	30
192	Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathies. *Orphanet Journal of Rare Diseases*, **2014**, 9, 121	4.2	30
191	Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. *Journal of Neuro-Oncology*, **2012**, 109, 45-52	4.8	30
190	The yeast HtrA orthologue Ynm3 is a protease with chaperone activity that aids survival under heat stress. *Molecular Biology of the Cell*, **2009**, 20, 68-77	3.5	30
189	Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia. *DMM Disease Models and Mechanisms*, **2012**, 5, 860-9	4.1	30
188	Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. *European Journal of Pharmacology*, **2000**, 400, 155-66	5.3	30

187	Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. *Experimental Neurology*, **1994**, 129, 175-82	5.7	30
186	Molecular pathogenesis of movement disorders: are protein aggregates a common link in neuronal degeneration?. *Current Opinion in Neurology*, **1999**, 12, 433-9	7.1	30
185	Cognitive Improvement and Brain Changes after Real-Time Functional MRI Neurofeedback Training in Healthy Elderly and Prodromal Alzheimer's Disease. *Frontiers in Neurology*, **2017**, 8, 384	4.1	29
184	Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes. *Movement Disorders*, **2010**, 25, 1284-8	7	29
183	Identification of inhibitor-of-differentiation 2 (Id2) as a modulator of neuronal apoptosis. *Journal of Neurochemistry*, **2002**, 80, 755-62	6	29
182	The impact of fraudulent and irreproducible data to the translational research crisis - solutions and implementation. *Journal of Neurochemistry*, **2016**, 139 Suppl 2, 253-270	6	28
181	Neurothrombectomy in acute ischaemic stroke: a prospective single-centre study and comparison with randomized controlled trials. *European Journal of Neurology*, **2016**, 23, 807-16	6	28
180	Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. *Journal of Neurology*, **2017**, 264, 1193-1203	5.5	27
179	Specific and disease stage-dependent episodic memory-related brain activation patterns in Alzheimer's disease: a coordinate-based meta-analysis. *Brain Structure and Function*, **2015**, 220, 1555-71	4	27
178	Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. *Annals of Clinical and Translational Neurology*, **2018**, 5, 128-137	5.3	27
177	Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila. *PLoS ONE*, **2012**, 7, e47452	3.7	27
176	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 171-179	5.5	27
175	Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: the effects of 3-acetylpyridine neurotoxicity. *Neuroscience*, **1997**, 81, 721-34	3.9	26
174	Going beyond the mean: Intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders. *Clinical Neuropsychologist*, **2019**, 33, 369-389	4.4	25
173	A global in vivo Drosophila RNAi screen identifies a key role of ceramide phosphoethanolamine for glial ensheathment of axons. *PLoS Genetics*, **2013**, 9, e1003980	6	25
172	Diffusion-weighted MRI in patients with symptomatic internal carotid artery disease. *Journal of Neurology*, **2002**, 249, 1168-74	5.5	25
171	Potassium deprivation-induced apoptosis of cerebellar granule neurons: cytochrome c release in the absence of altered expression of Bcl-2 family proteins. *Cellular Physiology and Biochemistry*, **1998**, 8, 194-201	3.9	25
170	Oculomotor abnormalities and MRI findings in idiopathic cerebellar ataxia. *Journal of Neurology*, **1994**, 241, 234-41	5.5	25

169	Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease? **2014**, 5, 63-75		25
168	Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder. *Parkinsonism and Related Disorders*, **2016**, 29, 10-6	3.6	24
167	Clinical significance of post-interventional cerebral hyperdensities after endovascular mechanical thrombectomy in acute ischaemic stroke. *Neuroradiology*, **2014**, 56, 41-50	3.2	24
166	Transient expression of Nxf, a bHLH-PAS transactivator induced by neuronal preconditioning, confers neuroprotection in cultured cells. *Brain Research*, **2007**, 1135, 1-11	3.7	24
165	Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. *Annals of the New York Academy of Sciences*, **1995**, 765, 100-10; discussion 116-8	6.5	24
164	Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors. *Journal of Neurochemistry*, **2009**, 108, 139-46	6	23
163	Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD. *Journal of Neurology*, **2018**, 265, 2548-2561	5.5	23
162	Novel FHL1 mutation in a family with reducing body myopathy. *Muscle and Nerve*, **2013**, 47, 127-34	3.4	22
161	Vaccination strategies in tauopathies and synucleinopathies. *Journal of Neurochemistry*, **2017**, 143, 467-488	6	22
160	Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. *Journal of Alzheimer's Disease*, **2011**, 25, 463-75	4.3	22
159	BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution. *Journal of Neurochemistry*, **2009**, 111, 801-7	6	22
158	Evoked potentials in multiple system atrophy (MSA). *Acta Neurologica Scandinavica*, **2000**, 101, 111-5	3.8	22
157	Diminished activation of motor working-memory networks in Parkinson's disease. *PLoS ONE*, **2013**, 8, e61786	3.7	22
156	Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease. *NeuroImage: Clinical*, **2015**, 7, 640-52	5.3	21
155	A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. *Neurobiology of Disease*, **2012**, 45, 591-600	7.5	21
154	PKC links Gq-coupled receptors to DAT-mediated dopamine release. *Journal of Neurochemistry*, **2010**, 114, 587-96	6	21
153	Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. *Neuroscience Letters*, **1994**, 177, 58-62	3.3	21
152	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. *EMBO Molecular Medicine*, **2020**, 12, e11803	12	20

151	Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene?. *Brain and Behavior*, **2016**, 6, e00451	3.4	20
150	Unobtrusive Nocturnal Heartbeat Monitoring by a Ballistocardiographic Sensor in Patients with Sleep Disordered Breathing. *Scientific Reports*, **2017**, 7, 13175	4.9	19
149	Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. *Parkinsonism and Related Disorders*, **2016**, 29, 112-6	3.6	19
148	Impact of gender and genetics on emotion processing in Parkinson's disease - A multimodal study. *NeuroImage: Clinical*, **2018**, 18, 305-314	5.3	18
147	Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. *Journal of Neurochemistry*, **2008**, 104, 757-65	6	18
146	Novel genetic and neuropathological insights in neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP). *Muscle and Nerve*, **2016**, 54, 328-33	3.4	18
145	Structural characteristics of the central nervous system in Friedreich ataxia: an in vivo spinal cord and brain MRI study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 615-617	5.5	17
144	Protein synthesis inhibition blocks consolidation of an acrobatic motor skill. *Learning and Memory*, **2004**, 11, 379-82	2.8	17
143	Apoptosis: its relevance to Parkinson's disease. *Clinical Neuroscience Research*, **2001**, 1, 427-433		17
142	Risk profile and treatment options of acute ischemic in-hospital stroke. *Journal of Neurology*, **2016**, 263, 550-7	5.5	16
141	CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration. *Journal of Neurochemistry*, **2014**, 129, 1013-23	6	16
140	Cognitive effects of deep brain stimulation for essential tremor: evaluation at 1 and 6 years. *Journal of Neural Transmission*, **2013**, 120, 1569-77	4.3	16
139	Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. *Neurogenetics*, **2010**, 11, 107-20	3	16
138	Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor. *Journal of Neurochemistry*, **2018**, 147, 678-691	6	16
137	Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias. *Journal of Neurology*, **2018**, 265, 2040-2051	5.5	16
136	199 years of Parkinson disease - what have we learned and what is the path to the future?. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 3-7	6	15
135	FYCO1 mediates clearance of α-synuclein aggregates through a Rab7-dependent mechanism. *Journal of Neurochemistry*, **2018**, 146, 474-492	6	15
134	Endonucleolytic DNA fragmentation is not required for apoptosis of cultured rat cerebellar granule neurons. *Neuroscience Letters*, **1998**, 245, 9-12	3.3	15

133	Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease. *Journal of Neurology*, **2006**, 253 Suppl 4, IV36-8	5.5	15
132	Nerve conduction studies in multiple system atrophy. *European Neurology*, **2000**, 43, 221-3	2.1	15
131	COVID-19 vaccine-associated cerebral venous thrombosis in Germany		15
130	Linking amyotrophic lateral sclerosis and spinal muscular atrophy through RNA-transcriptome homeostasis: a genomics perspective. *Journal of Neurochemistry*, **2017**, 141, 12-30	6	14
129	EPO regulates neuroprotective Transmembrane BAX Inhibitor-1 Motif-containing (TMBIM) family members GRINA and FAIM2 after cerebral ischemia-reperfusion injury. *Experimental Neurology*, **2019**, 320, 112978	5.7	14
128	Mice lacking Faim2 show increased cell death in the MPTP mouse model of Parkinson disease. *Journal of Neurochemistry*, **2016**, 139, 848-857	6	14
127	Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice. *Neurobiology of Aging*, **2013**, 34, 589-601	5.6	14
126	Body Mass Index Decline Is Related to Spinocerebellar Ataxia Disease Progression. *Movement Disorders Clinical Practice*, **2017**, 4, 689-697	2.2	14
125	Increased cerebral water content in hemodialysis patients. *PLoS ONE*, **2015**, 10, e0122188	3.7	14
124	Common data elements for clinical research in Friedreich's ataxia. *Movement Disorders*, **2013**, 28, 190-5	7	14
123	Mechanistic contributions of FBXO7 to Parkinson disease. *Journal of Neurochemistry*, **2018**, 144, 118-127	6	14
122	Faim2 contributes to neuroprotection by erythropoietin in transient brain ischemia. *Journal of Neurochemistry*, **2018**, 145, 258-270	6	13
121	Novel TPM3 mutation in a family with cap myopathy and review of the literature. *Neuromuscular Disorders*, **2014**, 24, 117-24	2.9	13
120	The proximal medial sural nerve biopsy model: a standardised and reproducible baseline clinical model for the translational evaluation of bioengineered nerve guides. *BioMed Research International*, **2014**, 2014, 121452	3	13
119	Modulation of hippocampal neuroplasticity by Fas/CD95 regulatory protein 2 (Faim2) in the course of bacterial meningitis. *Journal of Neuropathology and Experimental Neurology*, **2014**, 73, 2-13	3.1	13
118	150 years of Friedreich ataxia: from its discovery to therapy. *Journal of Neurochemistry*, **2013**, 126 Suppl 1, 1-3	6	13
117	Effects of deep brain stimulation of the cerebellothalamic pathways on the sense of smell. *Experimental Neurology*, **2010**, 222, 144-52	5.7	13
116	Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. *Neurological Research and Practice*, **2021**, 3, 17	3.2	13

115	Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. *Neurology*, **2013**, 81, 932-5	6.5	12
114	Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. *Journal of Neuro-Oncology*, **2003**, 61, 7-15	4.8	12
113	Neurochemical profiles in hereditary ataxias: A meta-analysis of Magnetic Resonance Spectroscopy studies. *Neuroscience and Biobehavioral Reviews*, **2020**, 108, 854-865	9	12
112	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. *Lancet Neurology, The*, **2021**, 20, 362-372	24.1	12
111	Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 559-565	5.5	11
110	EPO and TMBIM3/GRINA Promote the Activation of the Adaptive Arm and Counteract the Terminal Arm of the Unfolded Protein Response after Murine Transient Cerebral Ischemia. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	11
109	Involvement of the human ventrolateral thalamus in olfaction. *Journal of Neurology*, **2010**, 257, 2037-43	5.5	11
108	Extracellular domain splice variants of a transforming protein tyrosine phosphatase alpha mutant differentially activate Src-kinase dependent focus formation. *Genes To Cells*, **2007**, 12, 63-73	2.3	11
107	Gene dosage-dependent effects of bcl-2 expression on cellular survival and redox status. *Free Radical Biology and Medicine*, **2003**, 34, 1517-30	7.8	11
106	Muscarinic desensitization after septal lesions in rat hippocampus: evidence for the involvement of G-proteins. *Neuroscience*, **1992**, 47, 95-103	3.9	11
105	Morphological spectrum and clinical features of myopathies with tubular aggregates. *Histology and Histopathology*, **2013**, 28, 1041-54	1.4	11
104	Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. *Lancet Neurology, The*, **2020**, 19, 738-747	24.1	11
103	Screen-detected atrial fibrillation predicts mortality in elderly subjects. *Europace*, **2021**, 23, 29-38	3.9	11
102	Brain Structure and Degeneration Staging in Friedreich Ataxia: Magnetic Resonance Imaging Volumetrics from the ENIGMA-Ataxia Working Group. *Annals of Neurology*, **2021**, 90, 570-583	9.4	11
101	Adjuvant granulocyte colony-stimulating factor therapy results in improved spatial learning and stimulates hippocampal neurogenesis in a mouse model of pneumococcal meningitis. *Journal of Neuropathology and Experimental Neurology*, **2015**, 74, 85-94	3.1	10
100	Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke. *Journal of Molecular Medicine*, **2020**, 98, 833-847	5.5	10
99	Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP). *PLoS ONE*, **2017**, 12, e0170583	3.7	10
98	Early postictal serum lactate concentrations are superior to serum creatine kinase concentrations in distinguishing generalized tonic-clonic seizures from syncopes. *Internal and Emergency Medicine*, **2018**, 13, 749-755	3.7	10

97	CD95/Fas in the brain--not just a killer. *Cell Stem Cell*, **2009**, 5, 128-30	18	10
96	Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. *Psychological Medicine*, **2016**, 46, 2275-86	6.9	10
95	GAD Antibodies as Key Link Between Chronic Intestinal Pseudoobstruction, Autonomic Neuropathy, and Limb Stiffness in a Nondiabetic Patient: A CARE-Compliant Case Report and Review of the Literature. *Medicine (United States)*, **2015**, 94, e1265	1.8	9
94	Risk factors for idiopathic cerebellar ataxia of late onset. *Journal of the Neurological Sciences*, **1998**, 160, 171-4	3.2	9
93	Sodium-dependent Vitamin C transporter 2 deficiency impairs myelination and remyelination after injury: Roles of collagen and demethylation. *Glia*, **2017**, 65, 1186-1200	9	8
92	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. *Translational Neurodegeneration*, **2019**, 8, 11	10.3	8
91	Quantifiable evaluation of cerebellar signs in children. *Neurology*, **2015**, 84, 1225-32	6.5	8
90	Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). *Neurological Research and Practice*, **2019**, 1, 33	3.2	8
89	Spectrum of phenotypes and genotypes in Parkinson's disease. *Journal of Neurology*, **2002**, 249 Suppl 3, III/15-20	5.5	8
88	Onset features and time to diagnosis in Friedreich's Ataxia. *Orphanet Journal of Rare Diseases*, **2020** , 15, 198	4.2	8
87	Quantitative sensory testing predicts histological small fiber neuropathy in postural tachycardia syndrome. *Neurology: Clinical Practice*, **2020**, 10, 428-434	1.7	8
86	Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease. *International Journal of Methods in Psychiatric Research*, **2017**, 26,	4.3	7
85	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. *Cerebellum*, **2019**, 18, 896-909	4.3	7
84	Relevance of standard intravenous thrombolysis in endovascular stroke therapy of a tertiary stroke center. *Acta Neurologica Belgica*, **2018**, 118, 105-111	1.5	7
83	Standardized Assessment of Hereditary Ataxia Patients in Clinical Studies. *Movement Disorders Clinical Practice*, **2016**, 3, 230-240	2.2	7
82	Characterization of Naïve and Vitamin C-Treated Mouse Schwann Cell Line MSC80: Induction of the Antioxidative Thioredoxin Related Transmembrane Protein 1. *Journal of Proteome Research*, **2018**, 17, 2925-2936	5.6	7
81	The processing of lexical ambiguity in healthy ageing and Parkinson?s disease: role of cortico-subcortical networks. *Brain Research*, **2014**, 1581, 51-63	3.7	7
80	Grading of proximal internal carotid artery (ICA) stenosis by Doppler/duplex ultrasound (DUS) and computed tomographic angiography (CTA): correlation and interrater reliability in real-life practice. *Acta Neurologica Belgica*, **2017**, 117, 183-188	1.5	7

79	Myopathy with lobulated fibers, cores, and rods caused by a mutation in collagen VI. *Neurology*, **2012**, 79, 2288-90	6.5	7
78	Prediction of Survival With Long-Term Disease Progression in Most Common Spinocerebellar Ataxia. *Movement Disorders*, **2019**, 34, 1220-1227	7	6
77	Neurogenic pulmonary edema following seizures: A retrospective computed tomography study. *Epilepsy and Behavior*, **2019**, 94, 112-117	3.2	6
76	Semi-automated volumetry of MRI serves as a biomarker in neuromuscular patients. *Muscle and Nerve*, **2020**, 61, 600-607	3.4	6
75	A Learned Society's Perspective on Publishing. *Journal of Neurochemistry*, **2016**, 139 Suppl 2, 17-23	6	6
74	Gene therapy in Parkinson's disease. *Cell and Tissue Research*, **2004**, 318, 243-60	4.2	6
73	Changes in brain activation related to visuo-spatial memory after real-time fMRI neurofeedback training in healthy elderly and Alzheimer's disease. *Behavioural Brain Research*, **2020**, 381, 112435	3.4	6
72	Monitoring □synuclein multimerization in vivo. *FASEB Journal*, **2019**, 33, 2116-2131	0.9	6
71	Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson's disease on behalf of the German rapid eye movement sleep behavior disorder study group. *Sleep*, **2021**, 44,	1.1	6
70	New developments in diagnosis and treatment of Parkinson's disease--from basic science to clinical applications. *Journal of Neurology*, **2004**, 251 Suppl 6, VI/33-8	5.5	5
69	Magnetic resonance imaging□based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy **1999**, 45, 65		5
68	Myelinating Glia-Specific Deletion of Fbxo7 in Mice Triggers Axonal Degeneration in the Central Nervous System Together with Peripheral Neuropathy. *Journal of Neuroscience*, **2019**, 39, 5606-5626	6.6	4
67	Effects of selegiline and rasagiline on disease progression in Parkinson□ disease. *Basal Ganglia*, **2012**, 2, S41-S45		4
66	Basic science in Parkinson's disease: its impact on clinical practice. *Journal of Neurology*, **2011**, 258, S299-306	5.5	4
65	Therapeutic strategies for Parkinson's disease based on data derived from genetic research. *Journal of Neurology*, **2003**, 250 Suppl 1, I3-10	5.5	4
64	Frailty is an outcome predictor in patients with acute ischemic stroke receiving endovascular treatment. *Age and Ageing*, **2021**, 50, 1785-1791	3	4
63	A □Wrapin Targeting the N-Terminus of □Synuclein Monomers Reduces Fibril-Induced Aggregation in Neurons. *Frontiers in Neuroscience*, **2021**, 15, 696440	5.1	4
62	Atypical presentation of anti-Ma2-associated encephalitis with choreiform movement. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e557	9.1	3

61	Functional Characterization of Atrophy Patterns Related to Cognitive Impairment. *Frontiers in Neurology*, **2020**, 11, 18	4.1	3
60	Reviewer selection biases editorial decisions on manuscripts. *Journal of Neurochemistry*, **2018**, 146, 21	6	3
59	Reflections on 60 years of publication of the Journal of Neurochemistry. *Journal of Neurochemistry*, **2016**, 139 Suppl 2, 7-16	6	3
58	Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. *Journal of Neurochemistry*, **2008**, 77, 263-273	6	3
57	Very bright dorsal columns: spinal magnetic resonance imaging in funicular myelosis. *Archives of Neurology*, **2002**, 59, 147-8		3
56	Absence of SCA1 mutation in idiopathic cerebellar ataxia. *Journal of Neurology, Neurosurgery and Psychiatry*, **1994**, 57, 1439-40	5.5	3
55	Erythropoietin Abrogates Post-Ischemic Activation of the NLRP3, NLRC4, and AIM2 Inflammasomes in Microglia/Macrophages in a TAK1-Dependent Manner. *Translational Stroke Research*, **2021**, 1	7.8	3
54	Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease. *European Journal of Neurology*, **2021**, 28, 2855-2862	6	3
53	Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort. *Journal of Alzheimer's Disease*, **2021**, 79, 1661-1672	4.3	3
52	Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). *American Journal of Geriatric Psychiatry*, **2018**, 26, 1079-1090	6.5	3
51	Tubular aggregates in autoimmune Lambert-Eaton myasthenic syndrome. *Neuromuscular Disorders*, **2016**, 26, 880-884	2.9	2
50	The malleable brain - An educational review from students to students. *Journal of Neurochemistry*, **2017**, 142, 788-789	6	2
49	YouTube Videos on Parkinson's Disease are a Relevant Source of Patient Information. *Journal of Parkinson's Disease*, **2021**, 11, 833-842	5.3	2
48	A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. *Parkinsonism and Related Disorders*, **2021**, 90, 90-97	3.6	2
47	The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases **1997**, 193-197		2
46	Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo.. *Biomolecules*, **2022**, 12,	5.9	2
45	Quantitative sodium imaging using ultra-high field magnetic resonance imaging in patients with Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e042107	1.2	1
44	Effect of a multicomponent exercise intervention on brain metabolism: A randomized controlled trial on Alzheimer's pathology (Dementia-MOVE). *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12032	6	1

43	Anterior sacral meningocele infected with Fusobacterium in a patient with recently diagnosed colorectal carcinoma - a case report. *BMC Neurology*, **2017**, 17, 212	3.1	1
42	D26 Pathological tau signal in huntington disease an in vivo [18F]-AV-1451 pet imaging report. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A44.1-A44	5.5	1
41	Cardiovascular causes of emergency neurology presenting to an ICU. *Perfusion (United Kingdom)*, **2016**, 31, 271-80	1.9	1
40	Durch die kontinuierliche Blutdruckmessung lsst sich ein transienter orthostatischer Blutdruckabfall bei idiopathischer REM-Schlaf-Verhaltensstung nachweisen. *Klinische Neurophysiologie*, **2018**, 49, 127-132	0.2	1
39	Cardiac stress after electroconvulsive therapy and spontaneous generalized convulsive seizures: A prospective echocardiographic and blood biomarker study. *Epilepsy and Behavior*, **2019**, 101, 106565	3.2	1
38	Teaching neuroimages: combined retinal and cerebral hyperperfusion syndrome after carotid thromboendarterectomy. *Neurology*, **2013**, 81, e166-7	6.5	1
37	Neues zur Alzheimer Erkrankung. *Aktuelle Neurologie*, **2011**, 38, 234-241		1
36	Introduction: Targeted modulation of neuronal apoptosis: a double-edged sword?. *Brain Pathology*, **2000**, 10, 273-5	6	1
35	Beidseitige Stimmbandlhmung als Symptom einer Multisystematrophie (MSA). *Aktuelle Neurologie* , **1993**, 20, 170-173		1
34	Neurologische Nebenwirkungen der COVID-19-Impfung. *InFo Neurologie & Psychiatrie*, **2022**, 24, 32-43	0	1
33	What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. *Alzheimer's and Dementia*, **2021**, 17, 1843-1854	1.2	1
32	Increased Post-Hypoxic Oxidative Stress and Activation of the PERK Branch of the UPR in -Deficient Is Abrogated by Metformin. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
31	Posterior Cortical Atrophy: A Case Report of a 6-Year Natural Progression. *Alzheimer Disease and Associated Disorders*, **2016**, 30, 276-80	2.5	1
30	Posthypoxic behavioral impairment and mortality of Drosophila melanogaster are associated with high temperatures, enhanced predeath activity and oxidative stress. *Experimental and Molecular Medicine*, **2021**, 53, 264-280	12.8	1
29	Modern Interdisciplinary and Interhospital Acute Stroke Therapy-What Patients Think About It and What They Really Understand. *Journal of Stroke and Cerebrovascular Diseases*, **2018**, 27, 2669-2676	2.8	1
28	StrokeWatch: An Instrument for Objective Standardized Real-Time Measurement of Door-to-Needle Times in Acute Ischemic Stroke Treatment. *Journal of Stroke and Cerebrovascular Diseases*, **2021**, 30, 105962	2.8	1
27	Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis. *Therapeutic Advances in Neurological Disorders*, **2021**, 14, 17562864211035543	6.6	1
26	Gaze Palsy as a Manifestation of Todd's Phenomenon: Case Report and Review of the Literature. *Brain Sciences*, **2020**, 10,	3.4	0

25	Die Wertigkeit der zerebralen Computertomografie bei der Differenzialdiagnostik der akuten peripheren Fazialisparese. *Klinische Neurophysiologie*, **2014**, 45, 164-167	0.2	0
24	Small-molecule modulators of TRMT2A decrease PolyQ aggregation and PolyQ-induced cell death.. *Computational and Structural Biotechnology Journal*, **2022**, 20, 443-458	6.8	0
23	Heterozygous POLG variant Ser1181Asn co-segregating in a family with autosomal dominant axonal neuropathy, proximal muscle fatigability, ptosis, and ragged red fibers.. *Neurological Research and Practice*, **2022**, 4, 5	3.2	0
22	Increased neural motor activation and functional reorganization in patients with idiopathic rapid eye movement sleep behavior disorder. *Parkinsonism and Related Disorders*, **2021**, 92, 76-82	3.6	0
21	New Keys to Early Diagnosis: Muscle Echogenicity, Nerve Ultrasound Patterns, Electrodiagnostic, and Clinical Parameters in 150 Patients with Hereditary Polyneuropathies. *Neurotherapeutics*, **2021**, 1	6.4	0
20	Gaze Deviation and Paresis Score (GPS) Sufficiently Predicts Emergent Large Vessel Occluding Strokes. *Journal of Stroke and Cerebrovascular Diseases*, **2021**, 30, 105518	2.8	0
19	Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder - a clue to early peripheral autonomic and sensory dysfunction?. *Journal of Neurology*, **2021**, 1	5.5	0
18	Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease. *Neurobiology of Aging*, **2021**, 109, 31-42	5.6	0
17	Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study.. *Orphanet Journal of Rare Diseases*, **2022**, 17, 47	4.2	0
16	The cognitive profile of Friedreich ataxia: a systematic review and meta-analysis.. *BMC Neurology*, **2022**, 22, 97	3.1	0
15	Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study.. *NeuroImage: Clinical*, **2022**, 34, 103025	5.3	0
14	CO2-induzierte Beatmungspflichtigkeit aufgrund einer SOX1-Antik□per-positiven subakuten axonal-betonten sensomotorische Polyneuropathie. *Klinische Neurophysiologie*, **2015**, 46, 158-160	0.2	
13	60□Years of the Journal of Neurochemistry. *Journal of Neurochemistry*, **2016**, 139 Suppl 2, 5-6	6	
12	D14 Resting-state connectivity changes in huntington□ disease: a follow-up study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A38.3-A39	5.5	
11	Preface: The energetic brain - a review from students to students. *Journal of Neurochemistry*, **2019**, 151, 137-138	6	
10	Parkinson-Syndrom(e) - Neue Konzepte f□ eine sich ausbreitende Erkrankung?. *Aktuelle Neurologie* , **2013**, 40, 327-332		
9	Molecular imaging and its applications: visualization beyond imagination. *Journal of Neurochemistry* , **2013**, 127, 575-7	6	
8	Aorto-left-ventricular tunnel: A rare cause of cardioembolic stroke in a 42-year-old patient. *Neurology*, **2011**, 76, 2129	6.5	

List of Publications

7	Caspases in Neurodegeneration **2002**, 179-187	
6	Neurodegeneration **2005**, 335-355	
5	Apoptosis in neurodegenerative diseases **2005**, 80-93	
4	Molekulare Ursachen der Parkinson Krankheit. *E-Neuroforum*, **2005**, 11, 112-119	
3	Preface to an editorial controversy on α-synuclein: How good are cellular models?: This is a Preface for an Editorial controversy between Hilal A. Lashuel "Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get" and Tiago F. Outeiro "Alpha-synuclein oligomerization and aggregation: A model will always be a model" Read Hilal A. Lashuel's reply "Alpha-Synuclein oligomerization and aggregation: All models are useful" *Journal of Neurochemistry*, **2021**, 157, 861-871	6
2	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12223	5.2
1	Magnetic resonance imaging in spinocerebellar ataxias. *Cerebellum*, **2008**, 7, 1-11	4.3